keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's disease

keyword
https://www.readbyqxmd.com/read/28239983/targeted-deletion-of-gd3-synthase-protects-against-mptp-induced-neurodegeneration
#1
Yada Akkhawattanangkul, Panchanan Maiti, Yi Xue, Dipendra Aryal, William C Wetsel, David Hamilton, Stephen C Fowler, Michael P McDonald
Parkinson's disease is a debilitating neurodegenerative condition for which there is no cure. Converging evidence implicates gangliosides in the pathogenesis of several neurodegenerative diseases, suggesting a potential new class of therapeutic targets. We have shown that interventions that simultaneously increase the neuroprotective GM1 ganglioside and decrease the pro-apoptotic GD3 ganglioside-such as inhibition of GD3 synthase (GD3S) or administration of sialidase-are neuroprotective in vitro and in a number of preclinical models...
February 27, 2017: Genes, Brain, and Behavior
https://www.readbyqxmd.com/read/28239781/validation-of-the-promis-%C3%A2-measures-of-self-efficacy-for-managing-chronic-conditions
#2
Ann L Gruber-Baldini, Craig Velozo, Sergio Romero, Lisa M Shulman
PURPOSE: The Patient-Reported Outcomes Measurement Information System(®) (PROMIS(®)) was designed to develop, validate, and standardize item banks to measure key domains of physical, mental, and social health in chronic conditions. This paper reports the calibration and validation testing of the PROMIS Self-Efficacy for Managing Chronic Conditions measures. METHODS: PROMIS Self-Efficacy for Managing Chronic Conditions item banks comprise five domains, Self-Efficacy for Managing: Daily Activities, Symptoms, Medications and Treatments, Emotions, and Social Interactions...
February 26, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28239748/%C3%AE-synuclein-s-uniquely-long-amphipathic-helix-enhances-its-membrane-binding-and-remodeling-capacity
#3
Anthony R Braun, Michael M Lacy, Vanessa C Ducas, Elizabeth Rhoades, Jonathan N Sachs
α-Synuclein is the primary protein found in Lewy bodies, the protein and lipid aggregates associated with Parkinson's disease and Lewy body dementia. The protein folds into a uniquely long amphipathic α-helix (AH) when bound to a membrane, and at high enough concentrations, it induces large-scale remodeling of membranes (tubulation and vesiculation). By engineering a less hydrophobic variant of α-Synuclein, we previously showed that the energy associated with binding of α-Synuclein's AH correlates with the extent of membrane remodeling (Braun et al...
February 26, 2017: Journal of Membrane Biology
https://www.readbyqxmd.com/read/28239615/apomorphine-subcutaneous-injection-for-the-management-of-morning-akinesia-in-parkinson-s-disease
#4
Stuart Isaacson, Mark Lew, William Ondo, Jean Hubble, Thomas Clinch, Fernando Pagan
BACKGROUND: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON with levodopa are common. This open-label study aimed to assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. METHODS: The safety population included 127 enrolled patients, and the full analysis set (FAS) included 88 patients. Patients completed a 7-day levodopa baseline period recording their time-to-ON following each morning dose of levodopa...
January 2017: Movement Disorders Clinical Practice
https://www.readbyqxmd.com/read/28239526/weight-loss-in-the-early-stage-of-progressive-supranuclear-palsy
#5
Ayako Tsuge, Satoshi Kaneko, Reika Wate, Mitsuaki Oki, Masato Nagashima, Shinya Asayama, Masataka Nakamura, Kengo Fujita, Akemi Saito, Norihiro Takenouchi, Hirofumi Kusaka
OBJECTIVES: To clarify whether weight change in patients with Parkinson's disease (PD) or progressive supranuclear palsy (PSP) is caused by the disease itself or secondarily by other factors. MATERIALS AND METHODS: We conducted a retrospective analysis of 51 patients with PD and 14 patients with PSP, especially during the early stage of their diseases. All patients were independent in terms of their activities of daily living and did not have any feeding difficulty...
February 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28239501/consensus-on-the-definition-of-advanced-parkinson-s-disease-a-neurologists-based-delphi-study-cepa-study
#6
Maria-Rosario Luquin, Jaime Kulisevsky, Pablo Martinez-Martin, Pablo Mir, Eduardo S Tolosa
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To obtain consensus on the definition of APD, we performed a prospective, multicenter, Spanish nationwide, 3-round Delphi study (CEPA study). An ad hoc questionnaire was designed with 33 questions concerning the relevance of several clinical features for APD diagnosis. In the first-round, 240 neurologists of the Spanish Movement Disorders Group participated in the study. The results obtained were incorporated into the questionnaire and both, results and questionnaire, were sent out to and fulfilled by 26 experts in Movement Disorders...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28239455/the-underlying-mechanism-of-prodromal-pd-insights-from-the-parasympathetic-nervous-system-and-the-olfactory-system
#7
REVIEW
Shu-Ying Liu, Piu Chan, A Jon Stoessl
Neurodegeneration of Parkinson's disease (PD) starts in an insidious manner, 30-50% of dopaminergic neurons have been lost in the substantia nigra before clinical diagnosis. Prodromal stage of the disease, during which the disease pathology has started but is insufficient to result in clinical manifestations, offers a valuable window for disease-modifying therapies. The most focused underlying mechanisms linking the pathological pattern and clinical characteristics of prodromal PD are the prion hypothesis of alpha-synuclein and the selective vulnerability of neurons...
2017: Translational Neurodegeneration
https://www.readbyqxmd.com/read/28239348/genetic-determinants-of-parkinson-s-disease-can-they-help-to-stratify-the-patients-based-on-the-underlying-molecular-defect
#8
REVIEW
Sara Redenšek, Maja Trošt, Vita Dolžan
Parkinson's disease (PD) is a sporadic progressive neurodegenerative brain disorder with a relatively strong genetic background. We have reviewed the current literature about the genetic factors that could be indicative of pathophysiological pathways of PD and their applications in everyday clinical practice. Information on novel risk genes is coming from several genome-wide association studies (GWASs) and their meta-analyses. GWASs that have been performed so far enabled the identification of 24 loci as PD risk factors...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28239340/dopamine-induced-changes-in-g%C3%AE-olf-protein-levels-in-striatonigral-and-striatopallidal-medium-spiny-neurons-underlie-the-genesis-of-l-dopa-induced-dyskinesia-in-parkinsonian-mice
#9
Ryoma Morigaki, Shinya Okita, Satoshi Goto
The dopamine precursor, l-3,4-dihydroxyphenylalanine (l-DOPA), exerts powerful therapeutic effects but eventually generates l-DOPA-induced dyskinesia (LID) in patients with Parkinson's disease (PD). LID has a close link with deregulation of striatal dopamine/cAMP signaling, which is integrated by medium spiny neurons (MSNs). Olfactory type G-protein α subunit (Gαolf), a stimulatory GTP-binding protein encoded by the GNAL gene, is highly concentrated in the striatum, where it positively couples with dopamine D1 (D1R) receptor and adenosine A2A receptor (A2AR) to increase intracellular cAMP levels in MSNs...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/28238838/polyphenols-in-combination-with-%C3%AE-cyclodextrin-can-inhibit-and-disaggregate-%C3%AE-synuclein-amyloids-under-cell-mimicking-conditions-a-promising-therapeutic-alternative
#10
Saurabh Gautam, Sandip Karmakar, Radhika Batra, Pankaj Sharma, Prashant Pradhan, Jasdeep Singh, Bishwajit Kundu, Pramit K Chowdhury
Parkinson's disease is characterized by the presence of insoluble and neurotoxic aggregates (amyloid fibrils) of an intrinsically disordered protein α-synuclein. In this study we have examined the effects of four naturally occurring polyphenols in combination with β-cyclodextrin (β-CD) on the aggregation of α-synuclein in the presence of macromolecular crowding agents. Our results reveal that even at sub-stoichiometric concentrations of the individual components, the polyphenol-β-CD combination(s) not only inhibited the aggregation of the proteins but was also effective in disaggregating preformed fibrils...
February 23, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28238791/selol-an-organic-selenium-donor-prevents-lipopolysaccharide-induced-oxidative-stress-and-inflammatory-reaction-in-the-rat-brain
#11
Agnieszka Dominiak, Anna Wilkaniec, Henryk Jęśko, Grzegorz A Czapski, Anna M Lenkiewicz, Eliza Kurek, Piotr Wroczyński, Agata Adamczyk
Neuroinflammation and oxidative stress are key intertwined pathological factors in many neurological, particularly neurodegenerative diseases, such as Alzheimer's and Parkinson's disorders as well as autism. The present study was conducted to evaluate the protective effects of Selol, an organic selenium donor, against lipopolysaccharide (LPS)-mediated inflammation in rat brain. The results demonstrated that the peripheral administration of LPS in a dose of 100 μg/kg b.w. evoked typical pathological reaction known as systemic inflammatory response...
February 23, 2017: Neurochemistry International
https://www.readbyqxmd.com/read/28238714/neuroprotective-effects-of-kukoamine-a-on-neurotoxin-induced-parkinson-s-model-through-apoptosis-inhibition-and-autophagy-enhancement
#12
XiaoLong Hu, Qi Song, Xin Li, DanDan Li, Qiao Zhang, WeiHong Meng, QingChun Zhao
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in substantia nigra (SN). Our previous study demonstrated Kukoamine A to exhibit strong neuroprotective effects through anti-oxidative stress, anti-inflamation, anti-excitoxicity. In the present study, MPP(+) and MPTP-induced PD models of cell and animal were used to investigate the effects of KuA on PD. Our results demonstrated that KuA ameliorated cell loss and mitochondrial membrane potential (MMP) loss, and inhibited Bax/Bcl-2 ratio and MAPKs family that were induced by MPP(+)...
February 24, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28238712/the-prion-model-for-progression-and-diversity-of-neurodegenerative-diseases
#13
REVIEW
Barbara E Stopschinski, Marc I Diamond
The neuropathology of different neurodegenerative diseases begins in different brain regions, and involves distinct brain networks. Evidence indicates that transcellular propagation of protein aggregation, which is the basis of prion disease, might underlie the progression of pathology in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The prion model predicts specific patterns of neuronal vulnerability and network involvement on the basis of the conformation of pathological proteins...
February 23, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28238669/ellagic-acid-exerts-protective-effect-in-intrastriatal-6-hydroxydopamine-rat-model-of-parkinson-s-disease-possible-involvement-of-er%C3%AE-nrf2-ho-1-signaling
#14
Tourandokht Baluchnejadmojarad, Nafiseh Rabiee, Sedigheh Zabihnejad, Mehrdad Roghani
Parkinson's disease (PD) is a prevalent movement disorder in the elderly with progressive loss of mesencephalic dopaminergic neurons and incapacitating motor and non-motor complications. Ellagic acid is a natural phenolic compound with potent antioxidant and anti-inflammatory properties. In this study, we investigated its possible neuroprotective effect in 6-hydroxydopamine (6-OHDA) rat model of PD. Intrastriatal 6-OHDA-lesioned rats were pretreated with ellagic acid at a dose of 50 mg/kg/day for 1 week. Results showed that ellagic acid attenuates apomorphine-induced rotational bias and lowers the latency to initiate and the total time in the narrow beam task and this beneficial effect was partially abrogated following intracerebroventricular microinjection of estrogen receptor β (ERβ) antagonist...
February 23, 2017: Brain Research
https://www.readbyqxmd.com/read/28238650/which-patients-discontinue-issues-on-levodopa-carbidopa-intestinal-gel-treatment-italian-multicentre-survey-of-905-patients-with-long-term-follow-up
#15
Mariachiara Sensi, Giovanni Cossu, Francesca Mancini, Manuela Pilleri, Maurizio Zibetti, Nicola Modugno, Rocco Quatrale, Filippo Tamma, Angelo Antonini
OBJECTIVES: To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy. METHODS: Sixty Parkinson's Disease (PD) specialists in Italy were invited to complete a survey covering issues on clinical and practical aspects of LCIG therapy. RESULTS: Clinical features of 905 patients were collected retrospectively. The majority of centres reported the use of a multidisciplinary team, biochemistry testing, neurophysiological and neuropsychological tests before and after treatment, in addition to caregivers' training and patient's follow as outpatients...
February 21, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28238162/genetic-analysis-of-fgf20-in-chinese-patients-with-parkinson-s-disease
#16
Xiao-Yi Sun, Ling Wang, Lan Cheng, Nan-Nan Li, Zhong-Jiao Lu, Jun-Ying Li, Rong Peng
Sequence variants in fibroblast growth factor 20 (FGF20) have been reported to be associated with Parkinson's disease (PD). We genotyped the rs591323 variant in a total of 2220 Han Chinese subjects, including 1051 patients with sporadic PD and 1169 controls, to investigate the association between rs591323 and the risk of PD. In addition, we also conducted a stratified analysis according to age at onset of PD and compared the clinical characteristics of AA + AG subjects with GG subjects. In this study, we confirmed that the A allele of rs591323 in FGF20 reduces the risk of developing sporadic PD (P = 0...
February 25, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28237917/detection-of-motor-impairment-in-parkinson-s-disease-via-mobile-touchscreen-typing
#17
Teresa Arroyo-Gallego, Maria Jesus Ledesma-Carbayo, Alvaro Sanchez-Ferro, Ian Butterworth, Carlos Sanchez-Mendoza, Michele Matarazzo, Paloma Montero, Roberto Lopez-Blanco, Veronica Puertas-Martin, Rocio Trincado, Luca Giancardo
Mobile technology is opening a wide range of opportunities for transforming the standard of care for chronic disorders. Using smartphones as tools for longitudinally tracking symptoms could enable personalization of drug regimens and improve patient monitoring. Parkinson's disease (PD) is an ideal candidate for these tools. At present, evaluation of PD signs requires trained experts to quantify motor impairment in the clinic, limiting the frequency and quality of the information available for understanding the status and progression of the disease...
February 20, 2017: IEEE Transactions on Bio-medical Engineering
https://www.readbyqxmd.com/read/28237879/nadph-oxidase-derived-h2o2-mediates-the-regulatory-effects-of-microglia-on-astrogliosis-in-experimental-models-of-parkinson-s-disease
#18
Liyan Hou, Xueying Zhou, Cong Zhang, Ke Wang, Xiaofang Liu, Yuning Che, Fuqiang Sun, Huihua Li, Qingshan Wang, Dan Zhang, Jau-Shyong Hong
Astrogliosis has long been recognized in Parkinson's disease (PD), the most common neurodegenerative movement disorder. However, the mechanisms of how astroglia become activated remain unclear. Reciprocal interactions between microglia and astroglia play a pivotal role in regulating the activities of astroglia. The purpose of this study is to investigate the mechanism by which microglia regulate astrogliosis by using lipopolysaccharide (LPS) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse PD models...
February 22, 2017: Redox Biology
https://www.readbyqxmd.com/read/28237854/a-randomized-trial-of-relamorelin-for-constipation-in-parkinson-s-disease-move-pd-trial-results-and-lessons-learned
#19
Ronald F Pfeiffer
BACKGROUND: Bowel dysfunction, including both slow transit constipation and defecatory dysfunction, is a frequent and often troubling nonmotor manifestation of Parkinson's disease (PD). A variety of agents are employed for the treatment of constipation in PD, but dissatisfaction with available treatment approaches is common. Relamorelin is a synthetic ghrelin agonist that has demonstrated prokinetic properties within the gastrointestinal tract. METHODS: We carried out a multi-center, randomized, double-blind, placebo-controlled study of relamorelin in patients with PD experiencing chronic, inadequately controlled constipation...
February 14, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28237852/exploring-risk-factors-for-stuttering-development-in-parkinson-disease-after-deep-brain-stimulation
#20
Marina Picillo, Gustavo B Vincos, Francesco Sammartino, Andres M Lozano, Alfonso Fasano
BACKGROUND: Stuttering is a speech disorder with disruption of verbal fluency, occasionally present in Parkinson's disease (PD). PD co-incident stuttering may either worsen or improve after Deep Brain Stimulation (DBS). METHODS: Sixteen out of 453 PD patients (3.5%) exhibited stuttering after DBS (PD-S) and were compared with a group of patients without stuttering (PD-NS) using non-parametric statistics. RESULTS: After DBS, stuttering worsened in 3 out of 4 patients with co-incidental stuttering...
February 20, 2017: Parkinsonism & related Disorders
keyword
keyword
231
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"